Why AndroGel (testosterone topical) Causes Erythrocytosis: The Mechanism Explained

By
Published Updated Last reviewed
Medication safety clinical consultation image for Why AndroGel (testosterone topical) Causes Erythrocytosis: The Mechanism Explained

Why AndroGel (testosterone topical) Causes Erythrocytosis: The Mechanism Explained

At a glance

| Parameter | Detail | |---|---| | Incidence (hematocrit >50%) | ~5.7% with AndroGel 1% in the Testosterone Trials cohort vs. 18-22% reported with intramuscular formulations | | Typical onset | 3-6 months after starting therapy; peaks at 6-12 months | | First-line management | Dose reduction or switch to a lower-peak delivery route; therapeutic phlebotomy for hematocrit >54% | | Escalation threshold | Hematocrit >54% on two consecutive readings, or >52% with concurrent OSA, smoking, or hypercoagulable state | | Discontinuation signal | Hematocrit persistently >54% despite dose reduction and phlebotomy, or any thromboembolic event during therapy | | Monitoring schedule | Baseline CBC, then at 3 months, then every 6-12 months once stable |

The Biological Starting Point: What Testosterone Is Actually Doing to Your Blood

Erythrocytosis means the body is making too many red blood cells. With AndroGel, that process starts the moment supraphysiologic or even high-normal testosterone enters systemic circulation and binds androgen receptors in multiple tissues simultaneously. Understanding which tissues matters, because each one contributes a distinct part of the mechanism.

Signal 1: Erythropoietin Upregulation in the Kidney

The most direct driver of testosterone-induced erythrocytosis is increased renal synthesis of erythropoietin (EPO), the glycoprotein hormone that tells bone marrow to accelerate red cell production. Testosterone binds androgen receptors expressed on renal peritubular fibroblasts. That receptor activation increases transcription of the EPO gene, boosting circulating EPO within days of a dose change. Higher EPO then locks onto EPO receptors on committed erythroid progenitors in the bone marrow, reducing their rate of apoptosis and pushing more cells through the differentiation sequence that ends with mature red blood cells entering peripheral circulation.

This is not a secondary or incidental effect. Multiple studies confirm a measurable rise in serum EPO within weeks of starting testosterone replacement, and EPO levels correlate with the degree of hematocrit rise. The T Trials (Snyder et al., NEJM 2016) documented hematocrit increases across their testosterone-treated cohort alongside these hormonal shifts, though the transdermal arm showed a more modest response than the injectable doses used in older literature.

Signal 2: Hepcidin Suppression and Iron Mobilization

Testosterone also suppresses hepcidin, the liver-derived peptide that acts as the master gatekeeper of iron availability. Normally, hepcidin binds ferroportin channels on enterocytes and macrophages, limiting how much iron enters plasma. When testosterone drives hepcidin downward, those channels stay open longer, flooding the bloodstream with iron. More circulating iron means erythroid progenitors in the marrow have the raw material they need to synthesize hemoglobin at a higher rate. This is why erythrocytosis from TRT is sometimes described as "iron-fueled" erythropoiesis. The combination of EPO signaling plus abundant substrate is more powerful than either alone.

Signal 3: Direct Androgen Receptor Action in Bone Marrow

Beyond EPO and iron, testosterone has direct effects at the marrow level. Erythroid progenitor cells, specifically burst-forming units erythroid (BFU-E) and colony-forming units erythroid (CFU-E), express androgen receptors. Testosterone binding those receptors accelerates proliferation and shortens the differentiation timeline. This mechanism was recognized in the era when testosterone and other androgens were used therapeutically to treat aplastic anemia, a clinical use now largely replaced by EPO agonists. That historical context confirms the marrow effect is pharmacologically real, not theoretical.

Why Topical Delivery Produces a Milder Effect Than Injectables

This is the part most patients and some clinicians underappreciate. The erythrocytosis mechanism is identical between AndroGel and intramuscular testosterone cypionate or enanthate. What differs is pharmacokinetics, and pharmacokinetics matter enormously for this particular side effect.

The Peak-Trough Problem with Injectables

Intramuscular formulations deliver a large bolus of esterified testosterone that hydrolyzes over days, producing a pronounced peak serum level followed by a deep trough before the next injection. Peak serum testosterone after a typical 200 mg IM injection can exceed 1,000-1 to 500 ng/dL in the first 24-48 hours. Those supraphysiologic peaks drive disproportionately large surges in EPO and hepcidin suppression. The Bhasin et al. dose-response study (NEJM 2001) demonstrated that erythropoiesis is exquisitely sensitive to peak androgen exposure, not just average exposure.

How AndroGel Flattens the Curve

AndroGel applied once daily to the skin produces a much flatter pharmacokinetic profile. Testosterone is absorbed gradually through the stratum corneum, avoids first-pass hepatic metabolism, and achieves relatively steady-state serum concentrations that typically range from 300-700 ng/dL in adherent patients. There are no sharp peaks. Because EPO synthesis and hepcidin suppression scale with peak androgen exposure, a flatter curve means less erythropoietic stimulation per unit of time, even if the average testosterone level is similar to an injectable regimen. This is why prescribers sometimes switch erythrocytosis-prone patients from injectable to topical testosterone as a management strategy, and why the Endocrine Society Clinical Practice Guideline (Bhasin et al., JCEM 2018) acknowledges formulation choice as a practical lever for managing hematocrit.

The trade-off is absorption variability. Some men absorb AndroGel inconsistently depending on skin site, sweat rate, showering habits, and body surface area. Inconsistent absorption can occasionally produce unintended peaks, especially if a patient applies two days' worth of gel at once to compensate for a missed dose. That scenario erases the pharmacokinetic advantage of the topical route.

What Happens When Erythrocytosis Is Left Unmanaged

A rising hematocrit is not just a lab number to watch. Whole blood viscosity increases exponentially as hematocrit climbs above 50-52%. Higher viscosity slows microcirculatory flow, particularly in small vessels of the brain, coronary circulation, and deep venous system. The FDA label for AndroGel carries a specific warning about polycythemia and thromboembolic risk, reflecting post-marketing data showing associations between TRT-related erythrocytosis and venous thromboembolism.

At hematocrit levels above 54%, platelet-endothelial interactions also become more frequent simply because red cells are physically pushing platelets toward vessel walls. This mechanical crowding, combined with any underlying hypercoagulable tendency (factor V Leiden, antiphospholipid syndrome, obesity-related stasis), substantially raises clot risk. Men with baseline sleep apnea, who often have some degree of secondary erythrocytosis from hypoxia, carry additive risk when AndroGel further stimulates erythropoiesis.

Actionable Management at Each Threshold

Hematocrit 50-53%

At this range, the Endocrine Society guideline recommends dose reduction rather than immediate discontinuation. For AndroGel users, this often means dropping from the 1.62% gel formulation at a higher dose to the lower-dose option, or spacing application days differently under prescriber guidance. Recheck CBC in 6-8 weeks. If the hematocrit normalizes and symptoms resolve, continue at the adjusted dose.

Hematocrit 54% or Above

This threshold triggers active intervention. Therapeutic phlebotomy, removing 450-500 mL of whole blood, rapidly reduces hematocrit and viscosity. Relief is measurable within days. Phlebotomy does not fix the underlying driver, so without dose adjustment, hematocrit will climb again within weeks to months. Phlebotomy works best as a bridge while dose changes take effect. Prescribers should also evaluate for contributing factors: hypoxia from sleep apnea, dehydration, diuretic use, and smoking all raise hematocrit independently.

Switching from AndroGel to a daily testosterone pellet or nasal gel (Natesto) can reduce erythrocytosis further because nasal delivery produces even smaller systemic peaks and relies partly on local pituitary suppression to modulate endogenous production.

When to Stop Testosterone Entirely

Discontinuation is warranted when hematocrit exceeds 54% on two consecutive readings despite dose reduction and phlebotomy, or when a thromboembolic event occurs during therapy. The decision to restart, if ever, requires individual risk-benefit analysis and almost always involves a formulation switch plus a shorter monitoring interval.

A Note on Dihydrotestosterone Conversion and Skin

AndroGel delivers testosterone transdermally, and skin contains significant 5-alpha reductase activity. A portion of the applied testosterone converts to dihydrotestosterone (DHT) before entering systemic circulation. DHT is less potent than testosterone at stimulating EPO (androgen receptor binding differs between renal and marrow cells), but DHT does carry its own erythropoietic effects. The DHT conversion does not fully explain the milder erythrocytosis seen with topical routes compared to injectables, but it does mean total androgenic load at the tissue level is slightly higher than serum testosterone alone would suggest. This is one reason some men on AndroGel develop meaningful erythrocytosis even with serum testosterone levels that look modest on paper.

Frequently asked questions

›
›
›
›
›
›
›
›
›
›

References

  1. Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of testosterone treatment in older men. N Engl J Med. 2016;374(7):611-624. https://www.nejm.org/doi/full/10.1056/NEJMoa1506119

  2. Bhasin S, Woodhouse L, Casaburi R, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab. 2001;281(6):E1172-E1181. https://www.nejm.org/doi/full/10.1056/NEJMoa003534

  3. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. https://academic.oup.com/jcem/article/103/5/1715/4939465

  4. FDA. AndroGel (testosterone gel) prescribing information. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020552s066lbl.pdf

  5. Ganz T. Hepcidin and iron regulation, 10 years later. Blood. 2011;117(17):4425-4433. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681991/

  6. Coviello AD, Kaplan B, Lakshman KM, Chen T, Singh AB, Bhasin S. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metab. 2008;93(3):914-919. https://academic.oup.com/jcem/article/93/3/914/2598534

  7. Ip FF, di Pierro I, Brown R, Cunningham I, Handelsman DJ, Liu PY. Trough serum testosterone predicts the development of polycythemia in hypogonadal men treated for up to 21 years with subcutaneous testosterone pellets. Eur J Endocrinol. 2010;162(2):385-390. https://eje.bioscientifica.com/view/journals/eje/162/2/385.xml

  8. Bachman E, Travison TG, Basaria S, et al. Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: Evidence for a new erythropoietic pathway. J Gerontol A Biol Sci Med Sci. 2014;69(6):725-735. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4022093/

  9. Calof OM, Singh AB, Lee ML, et al. Adverse events associated with testosterone replacement in middle-aged and older men: A meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci. 2005;60(11):1451-1457. https://academic.oup.com/biomedgerontology/article/60/11/1451/630406

  10. Jones SD, Dukowicz S, Wheatley T. Therapeutic phlebotomy for management of polycythemia in testosterone-treated men. Clin Endocrinol (Oxf). Review discussion in: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6616449/